Sucralfate: prophylaxis of mucosal damage during cancer therapy.

Chemotherapy and radiotherapy of different malignancies may be complicated by a variety of side effects, some of which may be related mucosal damage.
There is increasing evidence that sucralfate reduces the severity of radiation-induced mucositis in the head and neck, esophagus, and the lower gastrointestinal tract. Sucralfate also seems to protect the skin during radiotherapy and to reduce chemotherapy-induced mucositis.
Further studies could be of interest to define the clinical significance of sucralfate in reducing the mucosal damage and increasing quality of life during an following cancer therapy.
AuthorsR Henriksson, L Franzén, C Edbom, B Littbrand
JournalScandinavian journal of gastroenterology. Supplement (Scand J Gastroenterol Suppl) Vol. 210 Pg. 45-7 ( 1995) ISSN: 0085-5928 [Print] NORWAY
PMID8578206 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Ulcer Agents
  • Antineoplastic Agents
  • Sucralfate
  • Anti-Ulcer Agents (administration & dosage, therapeutic use)
  • Antineoplastic Agents (adverse effects)
  • Humans
  • Intestinal Diseases (etiology, prevention & control)
  • Intestinal Mucosa (drug effects, pathology)
  • Neoplasms (therapy)
  • Radiotherapy (adverse effects)
  • Sucralfate (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: